Elecsys® pTau217 is the first blood test for Alzheimer’s disease pathology with a single‑assay design, intended to rule in ...

With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...

ZURICH, May 12 (Reuters) - Swiss drugmaker Roche has received the CE mark - a European regulatory clearance allowing sale in ...

Roche has grabbed a European CE mark for its second Alzheimer’s test, which can both confirm the disease and help rule it out. The Elecsys pTau217, developed in conjunction with Eli Lilly, is a blood ...

The Elecsys® SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of SARS-CoV-2 infection This new solution will run on all Roche cobas e immunochemistry ...

A sign at a diagnostics site for Swiss pharmaceutical giant Roche is seen as the company said problems at a new warehouse delayed the dispatch of some products ZURICH (Reuters) -Roche said on Friday ...

Roche aims to show you can still teach old biomarkers new tricks. The Big Pharma announced five additional uses for two of its mainstay heart tests which could extend the diagnostics’ reach to ...

Roche has agreed to acquire molecular residual disease (MRD) specialist, Saga Diagnostics and its platform in a $595m bid – further expanding its cancer monitoring portfolio. This merger will see ...

Basel, 24 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its COVID-19 At-Home ...

Swiss pharmaceutical company Roche has received European approval for a blood test that can detect and rule out Alzheimer’s ...